therapy
Therapy air ion a ZEptertol.

By: LDenes1

Visit link:
therapy - Video

Recommendation and review posted by Bethany Smith

Gene therapy to improve vision

By: BRC Ophthalmology

Go here to see the original:
Gene therapy to improve vision - Video

Recommendation and review posted by Bethany Smith

Penn State Hershey Institute for Personalized Medicine: A Tour
Dr. James Broach, director of Penn State Hershey Institute for Personalized Medicine, takes a brief tour of the institute, showing how samples are prepared f...

By: PennStateHershey

Read more here:
Penn State Hershey Institute for Personalized Medicine: A Tour - Video

Recommendation and review posted by sam

Growing Into Adulthood After Spinal Cord Injury
Visit our website at http://sci.washington.edu/. Everyone faces challenges when moving from the teen years into adulthood. Making this transition with a spin...

By: UWSpinalCordInjury

See the article here:
Growing Into Adulthood After Spinal Cord Injury - Video

Recommendation and review posted by sam

Management of Urinary Problems Caused by Spinal Cord Injury
Visit our website at http://sci.washington.edu/. Presented on October 13, 2009, Stephen Burns, MD, Staff Physician, SCI Service, VA Puget Sound Health Care S...

By: UWSpinalCordInjury

Read the original here:
Management of Urinary Problems Caused by Spinal Cord Injury - Video

Recommendation and review posted by sam

Stem Cell Therapy For Pets - Kye Before After
Amazing before and after footage of Kye, an 11 year old lab who received stem cell therapy for his arthritis. For more information about stem cell therapy fo...

By: NewmanVets

See the original post here:
Stem Cell Therapy For Pets - Kye Before

Recommendation and review posted by simmons

Editor's Choice Academic Journal Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Stem Cell Research Article Date: 21 Mar 2013 - 12:00 PDT

Current ratings for: Cell Therapy Shows Promise For Advanced Leukemia In Adults

3 (1 votes)

1 (1 votes)

Similar immune-system therapy has proven effective in children with this cancer as well as in adults with a similar type of leukemia, however, this is the first time this specific therapy has worked in adults.

The findings of the current study were based on five patients with acute lymphoblastic leukemia (ALL). T cells were extracted from the patient and modified to express a receptor for protein on other immune cells - called B cells - that are found in both cancerous and healthy tissues.

ALL is a cancer of the blood and bone marrow which progresses quickly - if left untreated, patients sometimes die within weeks. The first treatment is generally three phases of chemotherapy drugs.

For most patients, this puts the cancer in remission. However, it often comes back. The second treatment agenda is usually another round of chemotherapy followed by a bone marrow transplant.

The authors point out that when the cancer returns, it is often immune to many chemotherapy drugs. Therefore, Dr. Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City, and his colleagues set out to test a different approach.

The five participating patients received infusions of their altered T cells after undergoing standard chemotherapy. All five patients saw a total remission - for one patient this occured within just eight days, according to the researchers.

Read the original here:
Cell Therapy Shows Promise For Advanced Leukemia In Adults

Recommendation and review posted by Bethany Smith

Leukemia is never an easy disease to beat back, but adults with relapsed B cell acute lymphoblastic leukemia, or B-ALL, have especially grim prospects. This particular kind of blood cancer progresses quickly, and has only a 30 to 40 percent cure rate in adults. Chemotherapy drugs can sometimes clear out the cancer the first time around, but some patients relapse, requiring another round of chemotherapy, then a bone marrow transplant. But this second round can sometimes fail because the recurring leukemia proves resistant to the drugs.

Now, in a paper published Wednesday in the journal Science Translational Medicine, scientists have successfully treated B-ALL patients by inserting new genetic material into some of their T cells. The cell therapy allows the patients immune system to find and destroy the places where the blood cancer is hiding out.

In one case, the treatment cleared up a patients leukemia in a little more than a week.

We had hoped, but couldnt have predicted that the response would be so profound and rapid, Memorial Sloan-Kettering Cancer Center researcher Renier J. Brentjens told the New York Times.

Brentjens and his colleagues treated five B-ALL patients with some of their own T cells, which were genetically programmed to recognize a particular protein on the surface of B cells, the immune system cells that are affected by this kind of leukemia. The reengineered T cells then lay waste to all of the patients B cells, healthy and cancerous alike (the loss of healthy B cells can be treated later).

Were creating living drugs, senior author Michel Sadelain told the New York Times. Its an exciting story thats just beginning.

Still, the treatment is far from 100 percent perfect. Three of the five patients in the study have been in remission for anywhere between five months and two years. Another patient died of a blood clot after going in to remission, and another relapsed again possibly because a steroid treatment meant to control a side effect of the cell therapy may have wiped out the souped-up T cells before they could attack the B cells. The three survivors may yet relapse again.

And there are risks associated with the cell therapy. The T cells offensive onslaught can create whats called a cytokine storm, a potentially fatal immune chain reaction that usually induces an extremely high fever.

"This is very early in development," University of Pennsylvania researcher David Porter, who was not involved with the study, told US News & World Report. "We are just starting to learn about the short-term side effects, and we don't know about the long-term effectiveness or safety."

At the moment, this kind of cell therapy is being used as a lead-in to a bone marrow transplant. But in the future, doctors may be able to just use immunotherapy by itself.

Continue reading here:
Cell Therapy For Aggressive Leukemia Uses Patient's Own T Cells, Has Very Promising Results

Recommendation and review posted by Bethany Smith

Mar. 21, 2013 Food and environment can chemically alter your gene function and scientists have identified a gene that is consistently altered in obesity.

The gene LY86 was among a group of 100 genes identified as likely contributors to obesity through genome-wide association studies comparing the DNA of thousands of obese and lean individuals, said Dr. Shaoyong Su, genetic epidemiologist at the Medical College of Georgia at Georgia Regents University.

Su looked at progressively larger groups of obese versus lean individuals and found LY86 consistently and highly chemically altered, or methylated, in the obese individuals. "The association is solid; the methylation of this gene is important in obesity," Su said.

It's known that obesity is highly inheritable; that if parents are obese, children are at higher risk. However environment, including high-fat foods and chemical exposure, can put you at risk as well, said Su. Methylation is one way the body adjusts to its environment.

He received the 2013 Scott Grundy Fellowship Award for Excellence in Metabolism Research for his studies and is presenting the work this week during the Epidemiology and Prevention/Nutrition, Physical Activity and Metabolism Scientific Session of the American Heart Association in New Orleans.

Previously LY86 had been known as an inflammation gene and Su's studies show, in fact, it may be contributing to more than just obesity. He found high methylation of LY86 also was associated with increased inflammation -- a risk factor for a variety of maladies such as heart disease and cancer -- as well as insulin resistance, a cause of diabetes. This association also held up among a group of about 703 subjects that, like the general public, included obese, lean and average-weight individuals.

Now he wants to go back to the animal model to see whether methylation changes gene expression up or down in fat mice as well as fat, pregnant mice and their offspring. He believes that a lot of methylation starts in the womb and there are unfortunate real-life circumstances that support that theory.

For example, in the Dutch famine of 1944 near the end of World War II, babies born to starving mothers experienced DNA methylation that made them better able to survive such depravation, but in the more plentiful environment in which they grew up, put them at increased risk for cardiovascular disease as well as diabetes, obesity and other health problems.

He's already moving forward with more human studies as well, looking at a new group of lean and obese individuals, analyzing their DNA expression to see if increased methylation of LY86 means the gene is expressed more or less. Generally, higher methylation is thought to translate to lower gene expression.

He also wants to pin down whether methylation results from things like a high-fat diet, unfortunate genetics or both. These types of details may help explain why some individuals grow obese with a bad diet and little physical activity while others don't, Su said. It also may mean that positive environmental change, such as a better diet or more physical activity, can reverse at least some of the methylation. People may not get thin, for example, but they may reduce their risk for obesity-related disease, Su said.

Original post:
Scientists identify gene that is consistently altered in obese individuals

Recommendation and review posted by Bethany Smith

The Bible - Homeland - Part 2
Joshua conquers Jericho; Delilah betrays Samson as the Israelites battle the Philistines; Samuel anoints David king, a move that could throw the nation into ...

By: FHEFoxTVProductions

Original post:
The Bible - Homeland - Part 2 - Video

Recommendation and review posted by Bethany Smith

The Bible - Homeland - Part 1
Joshua conquers Jericho; Delilah betrays Samson as the Israelites battle the Philistines; Samuel anoints David king, a move that could throw the nation into ...

By: FHEFoxTVProductions

View original post here:
The Bible - Homeland - Part 1 - Video

Recommendation and review posted by Bethany Smith

Patriotism

By: Eric Bottelberghe

Read more from the original source:
Patriotism - Video

Recommendation and review posted by Bethany Smith

Obama #39;s Reptilian Secret Sevice Spotted AIPAC Conference 3 Angles (HD)
WATCH IN 720p !!!! Apparently one of Obama #39;s Secret Service Agent spooks shapeshifted into some weird humanoid during his speech at 2012 AIPAC Zionist Confer...

By: 4ReptilianResistance

Read the original:
Obama's Reptilian Secret Sevice Spotted AIPAC Conference 3 Angles (HD) - Video

Recommendation and review posted by Bethany Smith

New 2014 Subaru XV Crosstreck Hybrid
Read more here: http://www.carscoops.com/2013/03/subaru-to-reveal-new-2014-xv-crosstrek.html.

By: Carscoop

Here is the original post:
New 2014 Subaru XV Crosstreck Hybrid - Video

Recommendation and review posted by Bethany Smith

Virginia Tech

Virginia Tech researchers used a gene disruption technique to change the eye color of a mosquito, a critical step toward new strategies for disrupting the transmission of diseases such as dengue fever. The eye colors of these mosquitoes are varied because of cell-to-cell variability in the degree of gene editing.

By Alan Boyle, Science Editor, NBC News

Scientists at Virginia Tech have disrupted the genes that control eye color in mosquitoes, using a genetic-engineering technique that could also disrupt the transmission of diseases such as dengue fever.

The technique relies on two specially designed proteins that belong to a class known as transcription activator-like effector nucleases, or TALENs. The technique can target DNA at a specific site in an organism's genetic code, so precisely and efficiently that the journal Science has called the molecules "genomic cruise missiles."

Virginia Tech entomologist Zach Adelman prefers a different analogy. "They're basically a very, very fine-tuned pair of scissors," he told NBC News.

TALENs have been used to edit the genomes of animal and human cell cultures, but Adelman said the approach he and his colleagues used on the mosquito genome was different. Rather than trying to modify the function of a gene, the researchers aimed to disable a gene by snipping away at it. In the journal PLOS ONE, they describe how they targeted a gene whose protein product is essential for the production of eye pigment in Aedes aegypti, the mosquito species linked to the transmission of dengue fever.

Genetically engineered TALEN proteins were injected into the germ cells of mosquito embryos early in their development, with the intention of disrupting the coding for eye pigmentation that would be passed down to the next generation. When the targeted mosquitoes gave birth to baby bugs, a large percentage of them had light-colored eyes instead of the typical black eyes. The lack of pigment served as confirmation that the genetic code was wiped out.

The next step is to identify the genetic mechanisms in mosquitoes that play a role in virus transmission. When the right targets are found, the researchers will try to design a different set of molecular scissors to disrupt that genetic code.

Adelman said he's been working on molecular strategies to fight mosquito-borne diseases for a dozen years, and began the TALEN-based project just last May.

See the article here:
Disease-fighters disrupt mosquito's genes with molecular 'cruise missiles'

Recommendation and review posted by Bethany Smith

Virginia Tech

Virginia Tech researchers used a gene disruption technique to change the eye color of a mosquito, a critical step toward new strategies for disrupting the transmission of diseases such as dengue fever. The eye colors of these mosquitoes are varied because of cell-to-cell variability in the degree of gene editing.

By Alan Boyle, Science Editor, NBC News

Scientists at Virginia Tech have disrupted the genes that control eye color in mosquitoes, using a genetic-engineering technique that could also disrupt the transmission of diseases such as dengue fever.

The technique relies on two specially designed proteins that belong to a class known as transcription activator-like effector nucleases, or TALENs. The technique can target DNA at a specific site in an organism's genetic code, so precisely and efficiently that the journal Science has called the molecules "genomic cruise missiles."

Virginia Tech entomologist Zach Adelman prefers a different analogy. "They're basically a very, very fine-tuned pair of scissors," he told NBC News.

TALENs have been used to edit the genomes of animal and human cell cultures, but Adelman said the approach he and his colleagues used on the mosquito genome was different. Rather than trying to modify the function of a gene, the researchers aimed to disable a gene by snipping away at it. In the journal PLOS ONE, they describe how they targeted a gene whose protein product is essential for the production of eye pigment in Aedes aegypti, the mosquito species linked to the transmission of dengue fever.

Genetically engineered TALEN proteins were injected into the germ cells of mosquito embryos early in their development, with the intention of disrupting the coding for eye pigmentation that would be passed down to the next generation. When the targeted mosquitoes gave birth to baby bugs, a large percentage of them had light-colored eyes instead of the typical black eyes. The lack of pigment served as confirmation that the genetic code was wiped out.

The next step is to identify the genetic mechanisms in mosquitoes that play a role in virus transmission. When the right targets are found, the researchers will try to design a different set of molecular scissors to disrupt that genetic code.

Adelman said he's been working on molecular strategies to fight mosquito-borne diseases for a dozen years, and began the TALEN-based project just last May.

Read the original:
Disease-fighters disrupt mosquito's genes with molecular scissors

Recommendation and review posted by Bethany Smith

DUBLIN, March 21, 2013 /PRNewswire/ --

Nearly two out of three people in four major European countries have no awareness of personalised medicine - despite the fact that this evolving discipline has vast implications for Europe's healthcare issues and Europeans' personal health. These statistics presented today at the European Alliance for Personalised Medicine (EAPM) conference taking place in Dublin, in association with the Irish EU Presidency, were part of the PACE Cancer Perception Index that studied knowledge and attitudes about cancer treatment and care, the healthcare system and patient involvement. PACE, a Lilly Oncology initiative, stands for Patient Access to Cancer care Excellence.

The EAPM Conference on Innovation and Patient Access to Personalised Medicine brought together researchers, patients, healthcare professionals, payers, regulators, policymakers and industry to evaluate the potential and the development of personalised medicine in light of the European economic crisis.[i]

Irish Minister of Health Dr. James Reilly stressed the potential of personalised medicine "to provide solutions that are better tailored to the individual patient than traditional 'one size fits all' medicinal products."[ii]

"Personalised medicine is a promising concept," said Tonio Borg, European Union (EU) Commissioner for Health and Consumers. "As patients are divided into groups based on their individual, biological, genetic and genomic characteristics, medical interventions are tailored to those patients' needs."

"Hence, this new approach can help reduce the risk of undesirable adverse reactions and at the same time, make medicines more effective," said Mr. Borg. "And it also yields a maximum return on healthcare investment - a valuable argument for decision makers, in times of austerity."[iii]

Public Supports Personalised Medicine

A highlight of the conference was a work group that discussed the importance of informed, engaged and empowered patients where personalised medicine is concerned. Central to the discussion were the results of the PACE Cancer Perception Index: A Six-Nation, Public Opinion Survey of Cancer Knowledge and Attitudes.

"The PACE Cancer Perception Index devoted a considerable amount of time to the subject of personalised medicine, and what we found was both surprising and promising," said Sue Mahony, Ph.D., president, Lilly Oncology.

"While only one-third of respondents were aware of personalised medicine, the majority were supportive once the concept was introduced," Dr. Mahony said. "They not only recognised its benefits for them and society, but they expressed a willingness to help by being tested for personalised medicine, and by sharing their medical information."

Read the original post:
Global Survey Underscores Importance of Patient Education and Engagement in Personalised Medicine

Recommendation and review posted by Bethany Smith

SANTA CLARA, Calif.--(BUSINESS WIRE)--

Affymetrix, Inc. (AFFX) today announced that it has signed a contract with UK Biobank to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health. Affymetrix Axiom Genotyping Solution will be used to generate billions of high-quality genotypes which will provide UK Biobank and the research community with valuable insight to genetic factors underlying human diseases for improved prevention, diagnosis, and treatment of conditions such as heart disease, cancer, and diabetes.

Professor Rory Collins, UK Biobank CEO and Principal Investigator said: UK Biobank is pleased to join forces with Affymetrix for this next phase of the UK Biobank project. The two organizations will work closely together to ensure that world class data are provided quickly and securely to help scientists working on the causes of a wide range of life-threatening and disabling diseases. I urge health scientists everywhere to think carefully about how this resource could be used to help their research, and to register with UK Biobank. I am also very grateful to the half a million participants whose generosity and vision for the future has allowedthis resource to grow.

We are honored to partner with UK Biobank on this mission critical research initiative, said Dr. Frank Witney, President and CEO of Affymetrix. Earlier this year, we outlined our strategy to broaden our reach into the translational medicine, molecular diagnostics, and applied markets as part of our long-term transformation plan. This partnership reflects our efforts to strengthen our position in the growing translational medicine market and our commitment to work with visionary organizations such as the UK Biobank to produce the next generation of biological information that will improve healthcare.

Large scale genotyping studies such as the one undertaken by UK Biobank demand a flexible and scalable genomics analysis technology that produces a large amount of high quality data quickly, consistently, and cost-effectively. The unmatched flexibility, array reproducibility, and advanced design capabilities were key factors in UK Biobank adopting the Axiom Genotyping Solution. These platform capabilities have become increasingly important for genotyping studies in both the human and agbio markets as requirements shift away from very high-density, standardized designs toward customized high-fidelity arrays. We are very proud that our Axiom Genotyping Solution has been chosen for this incredibly important project, said Dr. Andy Last, EVP and General Manager of Genetic and Clinical Applications at Affymetrix.

Affymetrix expects to begin delivering data for the study towards the end of 2013. Affymetrix does not expect revenue from this contract to have a material impact in 2013, as it will start to recognize revenue in the latter part of this year, with the majority of the revenue expected to be recognized in 2014.

About UK Biobank:

UK Biobank is a major national health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses including cancer, heart diseases, stroke,diabetes, arthritis, osteoporosis, eye disorders,depressionand forms of dementia.UK Biobank recruited500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not.

About Affymetrix

Affymetrix technologies are used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes. More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit http://www.affymetrix.com.

Read more here:
Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Study of Genetic and ...

Recommendation and review posted by Bethany Smith

THE BOY WHO LIVED (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Want some gear? US Store: http://seananners.spreadshirt.com EU Store: http://seananners.spreadshirt....

By: SeaNanners

Here is the original post:
THE BOY WHO LIVED (The Hidden) - Video

Recommendation and review posted by Bethany Smith

"I Feel Like A Colon" with the Divine Ms Butt Meddler
Man! I feel like a colon! Why? The best thing about being a survivor Is the prerogative to show a little bun Women who are survivors of early onset ovarian o...

By: ButtMeddler

Read this article:
"I Feel Like A Colon" with the Divine Ms Butt Meddler - Video

Recommendation and review posted by Bethany Smith

Super Women Elite Desired Outcome Hangout - Jenn Jarecki Karen Flaherty

By: Jennifer Jarecki

Go here to read the rest:
Super Women Elite Desired Outcome Hangout - Jenn Jarecki

Recommendation and review posted by Bethany Smith

LOOK UP! (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Want some gear? US Store: http://seananners.spreadshirt.com EU Store: http://seananners.spreadshirt....

By: SeaNanners

See the original post here:
LOOK UP! (The Hidden) - Video

Recommendation and review posted by Bethany Smith

Why do we see illusions? - Mark Changizi
View full lesson: http://ed.ted.com/lessons/why-do-we-see-illusions-mark-changizi Why can #39;t our extremely complex eyes render simple optical illusions? Surpr...

By: TEDEducation

Continued here:
Why do we see illusions? - Mark Changizi - Video

Recommendation and review posted by Bethany Smith

Bad Genetics
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

Read the original:
Bad Genetics - Video

Recommendation and review posted by Bethany Smith

Back Workout With Mooji
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

View post:
Back Workout With Mooji - Video

Recommendation and review posted by Bethany Smith